How We Score

The Signal Score is a 0–100 summary of public regulatory, clinical-trial and company information about a manufacturer. It is a screening aid to help you decide where to look closer. It is not an audit, a site qualification or a prediction of performance. CDMOs cannot pay to change their score.

Who runs this site, and what it is not: About CDMO Signal.

Scores Currently Shown

The scores on profiles, in the directory and in search results come from the full rescoring run on 2026-10-29 under methodology v3.4; 28 companies have been rescored individually since.

Scores are recalculated in full, reviewed rescoring runs. They do not update automatically when new regulatory records arrive. A profile can therefore show regulatory records that are newer than its score; those records will count from the next rescoring run.

One exception: when we approve a correction a company submits to its own profile (sites, modalities, company type or notes, which can include a BIOSECURE Act note), that company is rescored straight away.

Composite Score (0–100)

Each company receives a weighted composite across four pillars. If the quality or operations pillar has no data, it is left out and the remaining weights are scaled up in proportion. A composite needs at least two pillars. The financial and capacity pillars start from a fixed baseline that our findings move up or down, so every profiled company has them. This means many scores rest only on financial and capacity information, with no regulatory or clinical-trial evidence. Profiles show which pillars are pending; we do not estimate a missing quality or operations pillar.

Quality Compliance 35%

  • FDA inspection outcomes (NAI/VAI/OAI). VAI and OAI outcomes deduct points, scaled by the number of observations; NAI adds a small credit
  • Recent inspections count more: an inspection's weight falls with age, reaching a floor of 30% after about three years
  • FDA 483 observations weighted by our severity scale: severity 5 counts 6×, 4 counts 3×, 3 counts 1×, 2 counts 0.4× and 1 counts 0.2× a typical observation
  • Repeat observations (same site, same regulation and subsystem within 36 months) count double
  • FDA warning letters: each letter on file deducts a fixed amount, weighted by its age the same way as inspections (full weight when new, falling to 30% at about three years old)
  • Active FDA import alerts and for-cause inspections deduct points
  • Three or more consecutive NAI inspections add a small bonus
  • EMA and MHRA statements of non-compliance deduct points, on a scale similar to an FDA OAI outcome. Compliant GMP certificates do not raise the EMA or MHRA sub-score, which starts at its maximum
  • When a company has records from more than one regulator, the sub-scores are blended in proportion to the number of records from each. A company with many compliant EMA or MHRA certificates therefore has its FDA deductions weighted less

Operations 25%

  • Number of ClinicalTrials.gov records matched to the company
  • Number of distinct sponsors in those records
  • Share of matched trials in Phase 2 or later
  • Share of matches made with high confidence
  • A small bonus for ten or more recruiting or ongoing trials

Trial records name sponsors and trial sites, not manufacturers. A match shows an association, not a confirmed manufacturing role.

Financial Stability 20%

  • Publicly traded or private
  • Ownership by a parent company, with more credit for parents on our list of established manufacturing groups
  • BIOSECURE Act exposure, based on our own review of the company (deduction)

Capacity Intelligence 20%

  • Number of manufacturing sites listed on the profile
  • Number of modalities listed on the profile

Site and modality lists are compiled from public sources, including company websites. They are not verified site by site and can be out of date. Job postings are not used in this pillar or in any other score.

FDA 483 Citation Subsystems & Severity

The Quality Compliance pillar weights each FDA 483 observation by the kind of issue (subsystem) and how serious it is (severity 1–5). Source: FDA's public 483 citation data. Profiles show FDA's published citation text; we do not paraphrase it.

Subsystems: each citation is placed in one of nine groups by fixed keyword rules applied to FDA's published description:

Data Integrity: records, audit trails, ALCOA, electronic records, computer system validation.

Environmental Monitoring: aseptic processing, sterility, particulates, cleanroom controls.

Process Validation: qualification, IQ/OQ/PQ, media fills, cleaning validation.

CAPA: investigations, root cause, deviations, OOS handling.

Laboratory Controls: testing, stability, analytical methods, reference standards.

Equipment & Facilities: calibration, maintenance, utilities, HVAC, water systems.

Documentation & Records: SOPs, batch records, written procedures.

Personnel & Training: competency, gowning, supervision.

Other: citations that match none of the eight groups above (often device or food regulations).

Severity 1–5 is our own scale, not an FDA rating. FDA does not say how serious each observation is, so we rate it ourselves from FDA's published wording and the regulation it cites. We rate the kind of problem the citation describes, not the facts of a particular inspection, so two sites given the same citation get the same rating.

Our severity guide

For each citation we ask three questions: which control failed; whether it was missing, not followed, or done but not written down; and how directly it could affect the product or the patient.

LevelWhat earns itTypical examples
5 — CriticalData that is falsified or not protected from change; sterility not assured for a sterile product; product released without quality approval or despite failing tests; required donor or infectious-disease testing not done.Lab data deleted with no audit trail. Aseptic process never validated. Batch shipped before release testing was finished.
4 — SeriousA core quality control failed, though the citation itself does not show harm: the quality unit does not approve or reject; failures, complaints or out-of-specification results not investigated; process not validated; release testing missing or not sound; contamination controls missing.Out-of-specification results not investigated. Manufacturing process not validated. Cleaning does not prevent cross-contamination.
3 — ModerateA real gap in a supporting quality process, one step removed from the product: training, change control, supplier checks, stability program, calibration and maintenance, labeling controls, batch-record review. Also: required reports to FDA not made.Equipment not calibrated on schedule. No written stability program. Supplier not qualified.
2 — MinorA paperwork lapse where the work appears to have been done but was not recorded, dated, signed or kept. Also: reports to FDA made late or incomplete.Distribution records incomplete. Training records not kept. Audit report not dated.
1 — TrivialA formal requirement with no plausible link to product quality. Rare.A registration or form-field formality.

A few adjustments apply:

  • A citation for a missing or unfollowed procedure takes the level of the process that procedure covers. If only the written procedure is missing and nothing suggests the process itself failed, it is one level lower, never below 2.
  • Contamination or validation problems in sterile manufacturing are at least 4.
  • Deleted, altered or unprotected records, or a missing audit trail, are always 5.
  • A missing record is usually 2, but 3 when the record is itself the control, such as the batch record for a critical step or an investigation report.

How ratings are produced today. The ratings shown now come from simpler keyword rules: each subsystem has a fixed level (data integrity 5; environmental monitoring and process validation 4; CAPA and laboratory controls 3; all others 2). These rules do not always match the guide above, and a rating can be off by a level in either direction. We are moving to rules built on this guide; when every citation has been rescored with them, we will say so here with the date. Our code also includes an optional language-model review that could raise (never lower) a rating. It has not been used: every rating shown today comes from the rules alone. Levels shown in the interface: 5 — Critical, 4 — Serious, 3 — Moderate, 2 — Minor, 1 — Trivial.

Repeat observations are flagged when the same site was cited for the same regulation, in the same subsystem, within the previous 36 months. They count double because a repeat suggests an earlier corrective action did not hold.

Data Sources

FDA: inspection classifications and 483 citations from the FDA Data Dashboard, and warning letters published by FDA. Collected in scheduled refreshes, not in real time.

EMA EudraGMDP: GMP certificates and statements of non-compliance for EU/EEA sites.

MHRA: UK GMP certificates and statements of non-compliance. Post-Brexit, UK records are separate from EudraGMDP.

Health Canada: HC GMP ratings from Health Canada's Drug and Health Product Inspections database, in Health Canada's own wording (for example "Compliant" or "Non-compliant"). An HC GMP rating is not the same as an inspection: for many sites outside Canada, Health Canada relies on FDA or EU inspections under mutual-recognition agreements. Shown on profiles; not scored.

ClinicalTrials.gov: 31,551 trial records, collected with searches for cell and gene therapy (gene therapy, CAR-T, cell therapy, viral vectors, gene editing). Companies are matched mainly by finding their name among a trial's listed sites, and through our own program library. A match is an association, not proof of a manufacturing relationship.

SEC EDGAR: 10-K, 10-Q and 8-K filings for publicly listed companies and parents. Shown on profiles; not scored.

Press monitoring: company announcements about partnerships, expansions, leadership changes and regulatory milestones. These are the company's own statements, not independent verification. Shown on profiles; not scored.

Company profiles: headquarters, manufacturing sites, modalities and company type, compiled by us from public sources including company websites.

How Often Is Data Updated?

The table shows the last time each source was successfully refreshed in full, and whether that is within its target schedule. Some automatic refreshes were paused in September 2026 while we added review steps, and are being restored one source at a time.

Source Target schedule Last full refresh Status
FDA inspections and 483 citations Weekly 2026-11-16 Up to date
FDA warning letters Daily 2026-11-21 Up to date
EMA GMP certificates Weekly 2026-11-19 Up to date
MHRA GMP certificates Weekly 2026-11-17 Up to date
ClinicalTrials.gov Weekly 2026-07-30 Overdue
SEC EDGAR filings Daily 2026-11-21 Up to date
Press monitoring Daily 2026-11-18 Up to date
Health Canada GMP ratings Weekly 2026-10-29 Overdue

Dates are in UTC. "Overdue" means the source has not been refreshed within its target schedule; records from it may be out of date. A refreshed record counts toward scores only after the next rescoring run.

Coverage and Scope

641 CDMOs profiled · 1,039 listed manufacturing sites · 5,226 regulatory records and SEC filings

These figures are counted live from our database and grow as profiles are added and checked. CDMOs are profiled companies we have classified as dedicated contract manufacturers or hybrids with a contract manufacturing arm; other profiled organisations (technology platforms, reagent suppliers, national centres and in-house pharma units) are not counted. Listed manufacturing sites are the site locations on those profiles, compiled from public sources and not verified site by site. Regulatory records and SEC filings are 719 FDA inspections, 498 FDA 483 citations, 29 FDA warning letters, 783 EMA GMP certificates, 3 EMA non-compliance statements, 213 MHRA GMP certificates, 2,325 Health Canada GMP ratings, 281 SEC filings, 375 PMDA (Japan) site accreditations, current, counting only records linked to those companies through a verified facility or the regulator's own published name.

CDMO Signal is not limited to one modality. Coverage began with cell and gene therapy and biologics and is being extended to small molecules, sterile fill-finish and other modalities, where it is still limited. Regulatory registries list many more manufacturers than we profile. A registry record shows that a site manufactures; it does not show whether the company takes contract work. Whether a company is a CDMO, and which type, comes from our own review of public information.

Limitations and Data Freshness

  • Scores lag the evidence. Apart from approved profile corrections, scores change only in a full rescoring run, so recent inspections, letters or certificates shown on a profile may not be reflected in its score yet.
  • Records can be attributed to the wrong company. We link records to companies by name, address and facility identifiers. Similar names cause errors, and we correct them as we find them.
  • Site lists can be incomplete or out of date. Companies open, sell and close sites faster than public sources record it.
  • Regulatory records do not establish contract manufacturing or modality. An inspection shows that a site was inspected, not what it makes for whom.
  • No record is not the same as a clean record. We cover FDA, EMA and MHRA, and show Health Canada GMP ratings and PMDA (Japan) site accreditations, which are approvals, not inspections. Inspections by other regulators, and inspections a regulator does not publish, are not visible to us.
  • Clinical-trial coverage is limited to cell and gene therapy. Trial data was collected for those modalities, so the Operations pillar says little about manufacturers working in other modalities, and for them it is usually missing.
  • Severity is our scale. FDA does not rate the severity of individual 483 observations. We rate FDA's standard citation wording, so a rating reflects the type of problem, not how widespread it was at that site. See our severity guide.
  • Company announcements are not evidence. Press releases and SEC filings describe what a company says about itself.

Hiring Activity: How We Collect It and Its Limits

What it is. A count of open job postings on a CDMO's public careers pages, grouped by function and site, with links to every original posting. It shows where a company is hiring. It isn't a measure of capacity, quality or financial health, and it doesn't change any Signal Score.

How it's collected. Once a day we read the job listings that careers sites publish for anyone to see: public job-board feeds (Greenhouse, Lever, Workday, SuccessFactors and similar) and the sitemaps those sites list for search engines. We follow each site's robots.txt. A site that asks automated readers not to collect it isn't collected, and its profile says so. We don't use LinkedIn or paid job databases.

Which postings count. Many companies share one careers site with a parent group or with businesses that aren't contract manufacturing. We count only the roles at the CDMO's own sites or units. When we can't separate them reliably, we show no count and say why, rather than a bigger number that isn't really the CDMO's. Placeholder listings such as "join our talent community" aren't counted.

Function and modality. Each posting is placed in one group (for example manufacturing, quality, process development, engineering) from its job title. The job board's department or the posting's text is used only when the title doesn't say. Modality words (for example AAV, mRNA, ADC) come from job titles only. In a hand-checked sample of 110 postings, the function group matched our reading 84% of the time, so treat the breakdown as approximate.

Known limits. Some boards publish only their newest ~100 postings, so we show "100+" there. Some feeds give no location, and we show how many postings lack one, so a site list may be incomplete. Postings can stay up after a role is filled, and one posting can cover several hires. Trends need history. Tracking started on October 26, 2026, and 30- and 90-day changes appear once that much history exists. A company's first day is counted as its starting point, not as new hiring.

How to read it. Hiring is a signal, not a statement by the company. The short "what this may mean" notes give the ordinary explanation alongside the hopeful one. Check the linked postings, and ask the company before relying on any of it.

What We Don't Score

Surveys, paid directory listings, sponsored placements and ratings submitted by CDMOs. Self-reported capabilities are not scored directly, but the site and modality lists used in the capacity pillar are compiled partly from company websites and from profile corrections companies submit, which we review before publishing.

Corrections

If you see a record attributed to the wrong company, an out-of-date site list or anything else that looks wrong, email hello@cdmosignal.com with the company name and the record. We review reports and correct errors we can confirm. Corrections to attribution are reflected in scores at the next rescoring run.

CDMO Types

Pure CDMO: dedicated contract manufacturers whose main business is manufacturing for sponsors.

Hybrid: companies with both their own pipelines and a contract manufacturing arm (e.g., Oxford Biomedica).

Platform: technology providers that enable or automate manufacturing (e.g., Cellares, MaxCyte).

Reagent/Material Supplier: suppliers of GMP reagents, media or materials used in biopharma manufacturing.

National Center: government-backed or non-profit manufacturing centres (e.g., Cell and Gene Therapy Catapult, CCRM).

Pharma Manufacturing Unit: manufacturing units of pharma or biotech companies that make mainly their own products. A unit that offers contract manufacturing to other companies is classed as Hybrid.

Only Pure CDMO and Hybrid profiles are counted as CDMOs in the figures on this site.

Frequently Asked Questions

How does CDMO Signal score CDMOs?

CDMO Signal uses a 4-pillar model: Quality Compliance (35%, FDA inspection, warning-letter and import-alert records plus EMA and MHRA GMP records), Operations (25%, ClinicalTrials.gov records matched to the company), Financial Stability (20%, ownership and listing status and parent-company backing), and Capacity Intelligence (20%, the company's listed sites and modalities). Press announcements and SEC filings are shown on profiles as company signals and do not change any score. Scores are built from public records and our own profile research. They are a screening aid, not an audit.

What data sources does CDMO Signal use?

Regulatory records from FDA (inspections, 483 citations and warning letters), EMA EudraGMDP and MHRA (GMP certificates and statements of non-compliance); ClinicalTrials.gov records for cell and gene therapy trials; SEC EDGAR filings and company press releases; and company profiles (sites, modalities, company type) compiled from public sources. The methodology page shows when each source was last refreshed.

Can CDMOs pay to influence their Signal Score?

No. CDMOs cannot pay for higher scores, featured placement, or removal of negative findings. Scores come from public records and our own profile research, and how they are calculated is described on this page.

How many CDMOs does CDMO Signal track?

CDMO Signal currently profiles 641 CDMOs (dedicated contract manufacturers and hybrids with a contract manufacturing arm), with 1,039 listed manufacturing sites and 5,226 regulatory records and SEC filings attributed to them. The number grows as profiles are added and checked. Coverage is not limited to one modality: it began with cell and gene therapy and biologics and is being extended to small molecules, sterile fill-finish and other modalities. You can request a lookup for any company not yet listed.

What is a CDMO?

A CDMO (contract development and manufacturing organization) develops and manufactures drug products for other companies — handling process development, GMP production, and regulatory support so sponsors don't have to build their own facilities.

What's the difference between a CDMO and a CMO?

A CMO (contract manufacturing organization) only manufactures; a CDMO adds development services — process and formulation development, analytical method development, and scale-up — alongside GMP manufacturing.

How do I choose a CDMO?

Compare CDMOs on regulatory track record (FDA inspections, EMA/MHRA GMP), relevant modality experience, capacity and timelines, and financial stability. CDMO Signal can help you shortlist on the public-record parts of that; capacity, timelines and site-level capability still need to be confirmed with each CDMO directly.